Tovorafenib
- Generic Name
- Tovorafenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12Cl2F3N7O2S
- CAS Number
- 1096708-71-2
- Unique Ingredient Identifier
- ZN90E4027M
- Background
Tovorafenib (TAK-580) is under investigation in clinical trial NCT02723006 (Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma).
- Associated Conditions
- -
- Associated Therapies
- -
The year in cancer: Advances made in 2024, predictions for 2025
In 2024, significant cancer treatment advances included CAR T-cell therapy, bispecific antibodies, and targeted therapies. Experts predict continued progress in immunotherapies, personalized medicine, and AI-driven research for 2025. Key lifestyle factors to reduce cancer risk include regular exercise, healthy eating, and avoiding smoking and excessive sun exposure.
Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade Glioma
Tovorafenib improves HRQOL in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma, showing enhancements in anxiety and cognition, though long-term QOL analysis is limited.
Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma
Tovorafenib, a type II RAF inhibitor, showed durable responses in pediatric BRAF-altered relapsed/refractory low-grade glioma patients during a drug holiday in the FIREFLY-1 trial. 97% of patients experienced no clinical progression, and 15% achieved additional tumor shrinkage. The safety profile remained consistent upon rechallenge. The FDA granted accelerated approval for tovorafenib in April 2024 for pediatric patients with BRAF-altered low-grade glioma.
Day One Biopharmaceuticals Co-Founder to Retire After Major FDA Drug Approval
Day One Biopharmaceuticals announces co-founder and Head of R&D, Dr. Samuel Blackman, will retire at the end of 2024, continuing as a strategic advisor. Dr. Elly Barry, Chief Medical Officer, will lead clinical and medical teams during the transition.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath